Baidu
map

Nat Commun:项鹏/王茂生合作揭示Nestin在肺癌中的作用机制

2019-11-10 酶美 BioArt

肿瘤抗氧化能力异常被认为是其恶性进展的机制之一。Nrf2是调控细胞氧化还原平衡的关键转录因子,其异常激活导致的抗氧化能力增强是肿瘤耐药的重要原因。系统解析Nrf2信号通路调控肿瘤细胞氧化应激的分子机制对于对揭示肿瘤发生发展和化疗抵抗具有重要意义。已有研究显示中间丝蛋白(intermediatefilament)作为细胞骨架成员帮助细胞抵抗外界多种应激,尤其是氧化应激,发挥细胞保护作用。

肿瘤抗氧化能力异常被认为是其恶性进展的机制之一。Nrf2是调控细胞氧化还原平衡的关键转录因子,其异常激活导致的抗氧化能力增强是肿瘤耐药的重要原因。系统解析Nrf2信号通路调控肿瘤细胞氧化应激的分子机制对于对揭示肿瘤发生发展和化疗抵抗具有重要意义。已有研究显示中间丝蛋白(intermediatefilament)作为细胞骨架成员帮助细胞抵抗外界多种应激,尤其是氧化应激,发挥细胞保护作用。

中山大学中山医学院项鹏课题组前期研究证实神经干细胞重要标志物巢蛋白(Nestin)作为第VI类中间丝蛋白,在肿瘤细胞中表达异常增高,且与胞内ROS水平、线粒体形态功能(Oncogene.2016)以及细胞衰老(Nat Commun.2018)密切相关。但其如何调控肿瘤细胞的氧化还原机制以及在恶性肿瘤进展中的生物学意义亟待阐明。

2019年11月6日,中山大学中山医学院项鹏课题组与高州市人民医院王茂生主任医师合作在Nature Communications发表了题为Nestin regulates cellular redox homeostasis in lung cancer through the Keap1–Nrf2 feedback loop的研究成果。首次揭示了Nestin通过竞争性结合keap1,抑制了Keap1对Nrf2的泛素化-蛋白酶体降解,促进了肺癌的氧化应激能力及化疗抵抗。

研究团队通过体内外实验证实Nestin与肺癌细胞的抗氧化能力直接相关,下调Nestin表达导致肿瘤细胞抗氧化基因(NQO1, GCLM, HO-1等)表达下调, Nrf2的泛素化降解增多,提示Nestin通过影响Nrf2蛋白稳定性发挥调控肿瘤细胞的氧化应激能力。机制研究发现,Nestin蛋白C-端的ESGE氨基酸序列(基序)与Keap1蛋白中的kelch结构域直接结合,抑制了Keap1对Nrf2的降解,促进了Nrf2的核转位;值得一提的是,Nestin启动子上游存在抗氧化反应元件(ARE),Nrf2可直接与ARE结合,促进Nestin表达,从而形成Nestin-Keap1-Nrf2-AREs正反馈调节轴,最终促进肿瘤的恶性进展及化疗抵抗。

综上,该研究首次揭示了Nestin在细胞氧化还原稳态维持中作用机制,为逆转肿瘤耐药提供了新的线索。

据悉,中山大学中山医学院干细胞与组织工程教育部重点实验室汪建成博士、卢绮莹博士生及中山大学附属第三医院肝脏外科蔡建业博士为论文的共同第一作者,中山大学中山医学院项鹏教授与高州市人民医院王茂生主任医师为共同通讯作者。

原始出处:
Wang J1,2, Lu Q1,2, Cai J2,3, et al.Nestin regulates cellular redox homeostasis in lung cancer through the Keap1-Nrf2 feedback loop.Nat Commun. 2019 Nov 6;10(1):5043. doi: 10.1038/s41467-019-12925-9.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1883992, encodeId=84631883992ae, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Mar 14 11:26:00 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051460, encodeId=e8092051460aa, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Feb 01 14:26:00 CST 2020, time=2020-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087624, encodeId=6a24208e62438, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Aug 23 04:26:00 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375020, encodeId=128f3e50205f, content=不能成为靶点,太重要了, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun Nov 10 20:41:21 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375010, encodeId=50383e5010d8, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sun Nov 10 13:48:57 CST 2019, time=2019-11-10, status=1, ipAttribution=)]
    2020-03-14 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1883992, encodeId=84631883992ae, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Mar 14 11:26:00 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051460, encodeId=e8092051460aa, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Feb 01 14:26:00 CST 2020, time=2020-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087624, encodeId=6a24208e62438, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Aug 23 04:26:00 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375020, encodeId=128f3e50205f, content=不能成为靶点,太重要了, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun Nov 10 20:41:21 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375010, encodeId=50383e5010d8, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sun Nov 10 13:48:57 CST 2019, time=2019-11-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1883992, encodeId=84631883992ae, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Mar 14 11:26:00 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051460, encodeId=e8092051460aa, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Feb 01 14:26:00 CST 2020, time=2020-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087624, encodeId=6a24208e62438, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Aug 23 04:26:00 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375020, encodeId=128f3e50205f, content=不能成为靶点,太重要了, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun Nov 10 20:41:21 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375010, encodeId=50383e5010d8, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sun Nov 10 13:48:57 CST 2019, time=2019-11-10, status=1, ipAttribution=)]
    2020-08-23 liuli5079
  4. [GetPortalCommentsPageByObjectIdResponse(id=1883992, encodeId=84631883992ae, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Mar 14 11:26:00 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051460, encodeId=e8092051460aa, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Feb 01 14:26:00 CST 2020, time=2020-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087624, encodeId=6a24208e62438, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Aug 23 04:26:00 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375020, encodeId=128f3e50205f, content=不能成为靶点,太重要了, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun Nov 10 20:41:21 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375010, encodeId=50383e5010d8, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sun Nov 10 13:48:57 CST 2019, time=2019-11-10, status=1, ipAttribution=)]
    2019-11-10 lovetcm

    不能成为靶点,太重要了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1883992, encodeId=84631883992ae, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Mar 14 11:26:00 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051460, encodeId=e8092051460aa, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Feb 01 14:26:00 CST 2020, time=2020-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087624, encodeId=6a24208e62438, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Aug 23 04:26:00 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375020, encodeId=128f3e50205f, content=不能成为靶点,太重要了, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun Nov 10 20:41:21 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375010, encodeId=50383e5010d8, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sun Nov 10 13:48:57 CST 2019, time=2019-11-10, status=1, ipAttribution=)]
    2019-11-10 1ddf0692m34(暂无匿称)

    学习了,谢谢分享

    0

相关资讯

Nature:非小细胞肺癌线粒体膜电位的体内成像

线粒体是细胞能量和代谢的重要调节剂,并且在维持癌细胞的生长和存活中起关键作用。

2019 ISRD-ATS:早筛早诊技术迎来突破,肺癌生存率有望不断提高

2019年10月24-27日,由中国健康促进基金会、北京医学奖励基金会、国际呼吸病学会(ISRD)共同主办,复旦大学附属中山医院呼吸与危重症医学科承办的“2019年国际呼吸病暨美国胸科学会联合会(ISRD-ATS)·2019中山呼吸论坛”在上海顺利召开。会议期间,有幸采访到ISRD、中国肺癌防治联盟主席、复旦大学附属中山医院的白春学教授,介绍肺癌早诊早治策略及新技术。

肺癌患者都需要基因检测吗?

普通人用检测来分析自己的疾病风险、遗传特质等信息,癌症患者应用基因检测来制定科学的治疗方案。就肺癌患者面对「基因检测」常见的问题做解答。

Nature:非小细胞肺癌新药——靶向药AMG 510的庐山真面目!

近日,美国、澳大利亚等多个医疗机构的研究人员报道提出了一种针对基因组突变蛋白的新型药物,并且在针对鼠的动物试验和前期临床首批给药组中已经被证明可有效抑制肿瘤的生长。相关研究发表于近日的《Nature》杂志中,该研究为缺乏有效治疗方法的癌症患者带来了新的希望

JAMA Oncol:酸奶、膳食纤维和肺癌之间,有什么关联?

近日,发表在美国医学会杂志肿瘤学子刊(JAMA Oncology)上一篇研究探讨了饮食与肺癌之间的关系。该研究分析了食用膳食纤维和酸奶是否可以降低患肺癌的风险。结果也许令人惊讶,但该研究团队得出了肯定的结论。

肺癌诊疗发展不断突破,抗血管生成联合治疗值得期待

近20年来,肺癌的治疗发生了翻天覆地的变化,当前肺癌的治疗手段愈加丰富,抗血管生成治疗作为其中之一,在肺癌的治疗中不可或缺。分享抗血管生成治疗药物在肺癌治疗中的应用现状和发展趋势,同时探讨不同类别抗血管生成药物之间不良反应的差异。

Baidu
map
Baidu
map
Baidu
map